{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Connolly RM"],"funding":["Avon Foundation for Women","Breast Cancer Research Foundation","Susan G. Komen","Abraxis","Cindy Rosencrans fund for TNBC","NCI NIH HHS","National Institutes of Health","NIH HHS","Merck"],"pagination":["107-116"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC5793219"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["167(1)"],"pubmed_abstract":["Background
Methylated gene markers have shown promise in predicting breast cancer outcomes and treatment response. We evaluated whether baseline and changes in tissue and serum methylation levels would predict pathological complete response (pCR) in patients with HER2-negative early breast cancer undergoing preoperative chemotherapy.Methods
The TBCRC008 trial investigated pCR following 12 weeks of preoperative carboplatin and albumin-bound paclitaxel + vorinostat/placebo (n = 62). We measured methylation of a 10-gene panel by quantitative multiplex methylation-specific polymerase chain reaction and expressed results as cumulative methylation index (CMI). We evaluated association between CMI level [baseline, day 15 (D15), and change] and pCR using univariate and multivariabl"],"journal":["Breast cancer research and treatment"],"pubmed_title":["Tumor and serum DNA methylation in women receiving preoperative chemotherapy with or without vorinostat in TBCRC008."],"pmcid":["PMC5793219"],"funding_grant_id":["P30 CA006973","LRTSTBCR07","02-2010-048","P50 CA088843","80022485","P50 CA88843","drug supply","316-2016"],"pubmed_authors":["Connolly RM","Fackler MJ","Watkins SP","Carpenter JT","Sukumar S","Zhou XC","Storniolo AM","Walsh B","Zhang Z","Boughey JC","Gabrielson EW","Goetz MP","Stearns V"],"additional_accession":[]},"is_claimable":false,"name":"Tumor and serum DNA methylation in women receiving preoperative chemotherapy with or without vorinostat in TBCRC008.","description":"Background
Methylated gene markers have shown promise in predicting breast cancer outcomes and treatment response. We evaluated whether baseline and changes in tissue and serum methylation levels would predict pathological complete response (pCR) in patients with HER2-negative early breast cancer undergoing preoperative chemotherapy.Methods
The TBCRC008 trial investigated pCR following 12 weeks of preoperative carboplatin and albumin-bound paclitaxel + vorinostat/placebo (n = 62). We measured methylation of a 10-gene panel by quantitative multiplex methylation-specific polymerase chain reaction and expressed results as cumulative methylation index (CMI). We evaluated association between CMI level [baseline, day 15 (D15), and change] and pCR using univariate and multivariabl","dates":{"release":"2018-01-01T00:00:00Z","publication":"2018 Jan","modification":"2026-04-29T20:56:23.212Z","creation":"2019-03-26T22:28:33Z"},"accession":"S-EPMC5793219","cross_references":{"pubmed":["28918548"],"doi":["10.1007/s10549-017-4503-2"]}}